CD109 Antibodies

Santa Cruz Biotechnology features a diverse variety of CD109 monoclonal antibodies for advanced research in cell biology and immunology. CD109 monoclonal antibodies are compatible with multiple research applications, including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), flow cytometry (FCM), and enzyme-linked immunosorbent assay (ELISA). CD109 is a glycosylphosphatidylinositol-anchored protein that plays a significant role in regulating cell growth and differentiation. Research has shown CD109's involvement in immune response modulation and tumor progression, making it an important target for cancer research. Understanding CD109 function is essential for developing therapeutic strategies against associated diseases. CD109 has emerged as a promising biomarker in various cancers, with potential applications in diagnosis and treatment monitoring. Recent studies have highlighted CD109's role in cell signaling pathways and tissue development. Ongoing research continues to uncover new functions of CD109 in both normal physiology and pathological conditions. Santa Cruz Biotechnology monoclonal antibodies for CD109 enable researchers worldwide to advance scientific understanding and potentially develop new therapeutic approaches.